Back HBV Disease Progression Liver Cancer/HCC

Liver Cancer/HCC

AASLD 2012: When Are HCV Direct-Acting Antivirals Needed, Who Should Be Prioritized?

When resources for hepatitis C treatment with new direct-acting antivirals are limited, findings from the U.S. suggest that previously untreated people with low HCV viral loads may stand a good chance of achieving sustained virological response without adding telaprevir or boceprevir to pegylated interferon and ribavirin, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this month in Boston. A related study suggests that younger hepatitis C patients with advanced liver disease should be prioritized for treatment with the new drugs. alt

Read more:

AASLD 2012: Nucleoside Analogs Reduce Hepatitis B Liver Cancer Risk, Cirrhosis Remains a Concern

Treatment of chronic hepatitis B with nucleoside/nucleotide analogs including lamivudine (Epivir-HBV) and entecavir (Baraclude) can reduce the risk of developing hepatocellular carcinoma, including cancer recurrence after successful resection, according to studies presented at the recent American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) and published in the Journal of the American Medical Association. alt

Read more:

EASL 2012: Brivanib Did Not Improve Overall Liver Cancer Survival, but Did Show Anti-tumor Activity

The experimental cancer drug brivanib did not lengthen overall survival for patients with hepatocellular carcinoma, but it did increase time to progression, demonstrating that it had anti-tumor activity, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona.alt

Read more:

Researchers Shed Light on how Hepatitis B Virus Causes Liver Cancer

Hepatitis B virus (HBV) is more often integrated in liver tumor cells than normal liver tissue cells, and multiple integrations may be linked to more aggressive disease progression and poorer survival, researchers reported in the May 27, 2012 advance online edition of Nature Genetics.alt

Read more:

Statins May Reduce Liver Cancer Risk among People with Hepatitis B

Statins, a class of drugs used to manage elevated blood cholesterol, may also play a role in fighting hepatocellular carcinoma (HCC) -- a form of primary liver cancer -- among people with chronic hepatitis B, according to a report in the January 23, 2012, advance online edition of the Journal of Clinical Oncology.

Read more: